Measles Resurgence: Why Molecular-Ready Sample Pathways Matter

The role of PrimeStore® MTM in supporting RT-PCR and surveillance workflows

Measles is once again a significant public health concern in England. While vaccination, case finding and contact tracing remain central to outbreak control, the current resurgence also highlights a less visible part of the response: the way samples are collected, transported and prepared for testing.

When suspected cases increase, laboratories need samples that can support reliable confirmation, surveillance and, where appropriate, further molecular characterisation. For RT-PCR workflows, the quality of the result does not depend on the assay alone. It also depends on what happens before the sample reaches the laboratory.

How is the sample collected? What medium is it placed into? How long is it in transit? Is cold-chain transport required? Is the sample still suitable for downstream molecular analysis when it arrives?

In a localised outbreak, these practical details can quickly become limiting factors.

What the UKHSA dashboard data shows

The latest UKHSA dashboard data reviewed for this article shows that measles activity in England in 2026 remains both paediatric-heavy and geographically concentrated. Outbreak pressure is rarely spread evenly across the health system. It can rise quickly in particular regions, local authorities, age groups and clinical settings.

Between 1^st January and 15^th June 2026, children aged 10 years and under accounted for approximately 60.2% of measles cases in England. Children aged 14 years and under accounted for approximately 66.4% of cases. The largest single age band was children aged 1 to 4 years, accounting for 27.5% of cases, followed by children aged 5 to 10 years at 21.0%. ^[1]

The regional pattern was also uneven. London accounted for 53.7% of cases in England, followed by the West Midlands at 17.4% and the North West at 10.9%. Together, these three regions accounted for 82.0% of cases. ^[1]

Higher-count upper-tier local authority data further illustrates this clustering, with Enfield, Birmingham, Haringey, Islington and Hertfordshire among the most prominent areas. Although these local authority figures should be interpreted carefully because areas with fewer than 10 cases are not shown in the relevant UKHSA reporting, they reinforce the point that outbreak pressure can be highly localised. ^[1,2]

Weekly onset data adds useful trend context. Across the first 24 weekly data points of each year, England recorded 792 laboratory-confirmed cases in the 2026 weekly onset series, compared with 535 over the equivalent early-year sequence in 2025 and 1,836 in 2024. In other words, 2026 activity remains materially above the equivalent 2025 pattern, although still below the larger outbreak pattern seen in early 2024. ^[1]

For laboratories and outbreak-response teams, the message is clear enough: measles activity remains elevated compared with the equivalent 2025 period and is concentrated in younger children and specific regions. That places practical pressure on sample collection, transport, testing and surveillance workflows.

Why this matters for molecular testing

Measles can be clinically distinctive, but early symptoms may overlap with other respiratory or rash-associated illnesses. Laboratory confirmation and surveillance therefore remain important parts of outbreak management.

For molecular testing, the pre-analytical phase is critical. A sample can begin to change from the moment it is collected. RNA may degrade. Transport may be delayed. Temperature may fluctuate. Samples may be collected in different clinical, community or outbreak-response settings. During a localised outbreak, sample volumes and logistics can change quickly.

Assay availability is only part of molecular outbreak readiness. The collection-to-result pathway also needs to be robust enough to support reliable testing from the point of collection onwards.

A molecular-ready sample pathway should ideally support:

• Nucleic acid preservation
• Respiratory sample compatibility
• Pre-analytical consistency
• Ambient transport where validated
• Compatibility with extraction and RT-PCR workflows
• Scalability during increased testing demand
• Local validation within the intended laboratory workflow

This is where molecular transport media such as PrimeStore® MTM become relevant.

HealthTrackRx: measles RT-PCR and surveillance workflow evidence

HealthTrackRx is a US-based molecular diagnostics laboratory specialising in PCR-based infectious disease testing, with next-morning results delivered nationwide across clinical areas including urgent care, women’s health, paediatrics and other community healthcare settings. Its high-throughput infectious disease testing model makes it a relevant example of how molecular laboratories can respond to outbreak pressure. ^[4]

During the 2025 US measles outbreak, HealthTrackRx developed measles qRT-PCR assays and produced conference poster data describing both assay validation and retrospective surveillance testing using samples collected in PrimeStore® MTM.

This is where the HealthTrackRx data are useful: they show what a practical measles molecular response looked like in a high-throughput PCR laboratory.

Both HealthTrackRx posters referenced in this article are available to download below.

The first poster, Performance Assessment of a Lab Developed Multiplex RT-PCR-Based Test for Measles (Rubeola), describes the development and analytical validation of a laboratory-developed multiplex RT-PCR assay for measles. The assay was designed to detect pan-measles virus, discriminate vaccine strain and include a human internal control within a single-well reaction. The poster describes testing across nasopharyngeal/nares swabs, oropharyngeal/throat swabs and cough sputum, with samples suspended in PrimeStore® MTM and analysed using a QuantStudio 5 Real-Time PCR System with TaqMan chemistry. ^[5]

The reported limit of detection for both pan-measles and vaccine-strain targets was 1.0 x 10¹ copies/µL. At 3x the limit of detection, the assay showed 100% detection across the assessed sample types. The poster also reported no observed cross-reactivity from tested background pathogens, no observed interference from 18 tested substances and 100% discrimination between wild-type measles and vaccine-strain measles. ^[5]

The significance lies not only in the measles target, but in the wider workflow: multiple respiratory sample types, a multiplex qRT-PCR format, internal control inclusion and wild-type/vaccine-strain discrimination were all assessed in a PrimeStore® MTM-based workflow.

The second poster, 2025 Measles Surveillance: Emerging Trends in a Post-Pandemic Landscape, reports a retrospective analysis of 947 respiratory specimens collected in PrimeStore® MTM and submitted to HealthTrackRx laboratories between 24^th March and 31^st October 2025. Samples were analysed for measles virus using a validated multiplex PCR assay, with results reviewed alongside patient age, geography and associated clinical information. ^[6]

The HealthTrackRx posters therefore provide useful workflow evidence. They show PrimeStore® MTM being used in both measles RT-PCR validation and measles surveillance testing, including workflows designed to detect pan-measles virus and discriminate between wild-type and vaccine-strain measles.

Where PrimeStore® MTM fits

PrimeStore® MTM is a molecular transport medium designed to support nucleic acid preservation and pathogen inactivation workflows. It is described as a single-step formulation intended to support pathogen inactivation, nucleic acid release and preservation, and ambient temperature sample transport and storage.

In practical terms, PrimeStore® MTM is positioned as a front-end sample optimisation tool for molecular testing workflows. Its role is not to diagnose measles, but to support the condition and molecular readiness of the sample before extraction and amplification.

Implications for outbreak preparedness

The 2026 measles data from across England show why front-end sample handling matters. Cases are concentrated in younger children and in specific regions, which can create localised pressure on healthcare settings, health protection teams, sample transport and laboratories.

The HealthTrackRx posters show how PrimeStore® MTM has been used in practical measles molecular workflows, including RT-PCR validation and surveillance testing. Viewed together, the UKHSA and HealthTrackRx data bring the pre-analytical pathway into focus: reliable molecular testing depends on more than the assay itself. It depends on the whole pathway from collection to result.

For laboratories reviewing their measles molecular testing workflows, useful questions include:

• Are current collection media optimised for molecular testing?
• How robust is the pathway when samples are collected outside the main laboratory?
• Is cold-chain transport a practical constraint?
• How long might samples remain in transit before extraction?
• Is the sample suitable for downstream RT-PCR, reflex testing or further molecular characterisation?
• Has the transport medium been validated with the intended sample type, extraction chemistry and assay?
• Are biosafety requirements clearly understood and locally risk assessed?

PrimeStore® MTM may be relevant where laboratories are reviewing the front end of their molecular testing pathway, particularly where nucleic acid preservation, workflow consistency and ambient transport are priorities. Any use in a measles workflow should be locally validated and aligned with UKHSA guidance and reference laboratory requirements. ^[3]

Conclusion

The resurgence of measles in England is not only a vaccination and public health story. It is also a reminder that molecular outbreak response depends on robust sample pathways.

The latest UKHSA dashboard data reviewed for this article show a paediatric-heavy and geographically concentrated case profile in 2026. HealthTrackRx scientific posters show PrimeStore® MTM being used in measles RT-PCR validation and surveillance workflows. Together, these evidence strands highlight the importance of sample collection, transport and molecular readiness during outbreak response.

PrimeStore® MTM should be considered as a molecular sample pathway tool, not as a measles diagnostic. Its relevance lies in its documented use in measles molecular workflows and its broader role in supporting nucleic acid preservation, ambient transport and pathogen inactivation workflows across other infectious disease contexts.

For laboratories preparing for resurgence, the key question is not only which assay is used. It is whether the sample pathway supports reliable molecular testing from the point of collection onwards.

 

Get in touch below with any questions about your lab’s molecular testing pathway or  for more information about PrimeStore® MTM. 

 

References

[1] UKHSA Measles Dashboard. Data reviewed included age distribution, regional distribution, upper-tier local authority case counts and weekly onset data. Cumulative age, region and local authority exports covered the period 1^st January to 15^th June 2026. Weekly onset data were reviewed across the first 24 weekly data points of 2026 and equivalent early-year sequences in 2025 and 2024. Accessed 1^st July 2026. CSV exports on file at VH Bio.

[2] UKHSA. Confirmed cases of measles in England by month, age, region and upper-tier local authority: 2026. GOV.UK. URL: https://www.gov.uk/government/publications/measles-epidemiology-2023-to-2026/confirmed-cases-of-measles-in-england-by-month-age-region-and-upper-tier-local-authority-2026. Accessed 1^st July 2026.

[3] UKHSA. National measles guidelines. GOV.UK. URL: https://www.gov.uk/government/publications/national-measles-guidelines. Accessed 1^st July 2026.

[4] HealthTrackRx. Faster, Reliable Diagnostics for Improved Patient Outcomes. URL: https://www.healthtrackrx.com/practitioners/. Accessed 1^st July 2026.

[5] Upadhyay P, Layton S, Singh V. Performance Assessment of a Lab Developed Multiplex RT-PCR-Based Test for Measles (Rubeola). HealthTrackRx conference poster/platform presentation, AMP 2025 Annual Meeting & Expo, Association for Molecular Pathology, Boston, MA, 11–15 November 2025. Poster/Presentation ID: ID047; Abstract number: 2169538; Category: Infectious Diseases. PDF available to download from this page.

[6] Upadhyay P, Singh V. 2025 Measles Surveillance: Emerging Trends in a Post-Pandemic Landscape. HealthTrackRx conference poster, AMP 2025 Annual Meeting & Expo, Association for Molecular Pathology, Boston, MA, 11–15 November 2025. Poster number: ID033; Abstract number: 2169461; Category: Infectious Diseases. PDF available to download from this page.